Literature DB >> 17855476

Subtype-selective corticotropin-releasing factor receptor agonists exert contrasting, but not opposite, effects on anxiety-related behavior in rats.

Y Zhao1, G R Valdez, E M Fekete, J E Rivier, W W Vale, K C Rice, F Weiss, E P Zorrilla.   

Abstract

The corticotropin-releasing factor (CRF) system mediates stress responses. Extrahypothalamic CRF1 receptor activation has anxiogenic-like properties, but anxiety-related functions of CRF2 receptors remain unclear. The present study determined the effects of intracerebroventricular administration of a CRF2 agonist, urocortin 3, on behavior of male Wistar rats in the shock-probe, social interaction, and defensive withdrawal tests of anxiety-like behavior. Equimolar doses of stressin1-A, a novel CRF1 agonist, were administered to separate rats. The effects of pyrazolo[1,5-a]-1,3,5-triazin-4-amine,8-[4-(bromo)-2-chlorophenyl]-N, N-bis(2-methoxyethyl)-2,7-dimethyl-(9Cl) (MJL-1-109-2), a CRF1 antagonist, on behavior in the shock-probe test also were studied. Stressin1-A increased anxiety-like behavior in the social interaction and shock-probe tests. Stressin1-A elicited behavioral activation and defensive burying at lower doses (0.04 nmol), but it increased freezing, grooming, and mounting at 25-fold higher (1-nmol) doses. Conversely, systemic administration of MJL-1-109-2 (10 mg/kg) had anxiolytic-like effects in the shock-probe test. Unlike stressin1-A or MJL-1-109-2, i.c.v. urocortin 3 infusion did not alter anxiety-like behavior in the shock-probe test across a range of doses that reduced locomotion and rearing and increased grooming. Urocortin 3 also did not decrease social interaction, but it decreased anxiety-like behavior in the defensive withdrawal test at a 2-nmol dose. Thus, i.c.v. administration of CRF1 and CRF2 agonists produced differential, but not opposite, effects on anxiety-like behavior. Urocortin 3 (i.c.v.) did not consistently decrease or increase anxiety-like behavior, the latter unlike effects seen previously after local microinjection of CRF2 agonists into the septum or raphe. With increasing CRF1 activation, however, the behavioral expression of anxiety qualitatively changes from "coping" to "noncoping" and offensive, agonistic behaviors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17855476     DOI: 10.1124/jpet.107.123208

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  33 in total

1.  Corticosteroid-dependent plasticity mediates compulsive alcohol drinking in rats.

Authors:  Leandro F Vendruscolo; Estelle Barbier; Joel E Schlosburg; Kaushik K Misra; Timothy W Whitfield; Marian L Logrip; Catherine Rivier; Vez Repunte-Canonigo; Eric P Zorrilla; Pietro P Sanna; Markus Heilig; George F Koob
Journal:  J Neurosci       Date:  2012-05-30       Impact factor: 6.167

Review 2.  Corticotropin releasing factor: a key role in the neurobiology of addiction.

Authors:  Eric P Zorrilla; Marian L Logrip; George F Koob
Journal:  Front Neuroendocrinol       Date:  2014-01-20       Impact factor: 8.606

3.  Polymorphism in the corticotropin-releasing factor receptor 1 (CRF1-R) gene plays a role in shaping the high anxious phenotype of Marchigian Sardinian alcohol-preferring (msP) rats.

Authors:  Andrea Cippitelli; Lydia O Ayanwuyi; Estelle Barbier; Esi Domi; Jose M Lerma-Cabrera; Francisca Carvajal; Giulia Scuppa; Hongwu Li; Massimo Ubaldi; Markus Heilig; Marisa Roberto; Roberto Ciccocioppo
Journal:  Psychopharmacology (Berl)       Date:  2014-09-27       Impact factor: 4.530

Review 4.  Deciphering the interaction of the corticotropin-releasing factor and serotonin brain systems in anxiety-related disorders.

Authors:  Judith R Homberg; Candice Contet
Journal:  J Neurosci       Date:  2009-11-04       Impact factor: 6.167

Review 5.  Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism.

Authors:  Eric P Zorrilla; Markus Heilig; Harriet de Wit; Yavin Shaham
Journal:  Drug Alcohol Depend       Date:  2013-01-05       Impact factor: 4.492

6.  Modification of anxiety-like behaviors by nociceptin/orphanin FQ (N/OFQ) and time-dependent changes in N/OFQ-NOP gene expression following ethanol withdrawal.

Authors:  Harinder Aujla; Rosalia Cannarsa; Patrizia Romualdi; Roberto Ciccocioppo; Rémi Martin-Fardon; Friedbert Weiss
Journal:  Addict Biol       Date:  2012-07-15       Impact factor: 4.280

Review 7.  The CRF system, stress, depression and anxiety-insights from human genetic studies.

Authors:  E B Binder; C B Nemeroff
Journal:  Mol Psychiatry       Date:  2009-12-15       Impact factor: 15.992

Review 8.  Role of CRF receptor signaling in stress vulnerability, anxiety, and depression.

Authors:  Richard L Hauger; Victoria Risbrough; Robert H Oakley; J Alberto Olivares-Reyes; Frank M Dautzenberg
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

9.  Social defeat stress activates medial amygdala cells that express type 2 corticotropin-releasing factor receptor mRNA.

Authors:  E M Fekete; Y Zhao; C Li; V Sabino; W W Vale; E P Zorrilla
Journal:  Neuroscience       Date:  2009-04-07       Impact factor: 3.590

Review 10.  The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction.

Authors:  James P Burkett; Larry J Young
Journal:  Psychopharmacology (Berl)       Date:  2012-08-11       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.